A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Conditions

• Obesity
• Overweight and Obesity

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Mazdutide — DRUG
  Administered subcutaneous (SC)
• Placebo — DRUG
  Administered SC

Study Details

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with Mazdutide compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.

Key Dates

Start date

Nov 17, 2023

Status verified

Mar 2026

Primary completion

Jan 22, 2025

Completion

Jul 9, 2025

Study Design

Enrollment

179 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: 3/6 Milligrams (mg) Mazdutide
  Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (3 or 6 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-31, then 6 mg from Weeks 32-48.
• Experimental: 10 mg Mazdutide
  Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (10 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-7, 6 mg from Weeks 8-11, 8 mg from Weeks 12-15, and then 10 mg from Weeks 16-48.
• Experimental: 16 mg Mazdutide
  Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (16 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-7, 6 mg from Weeks 8-11, 9 mg from Weeks 12-15, 12 mg from Weeks 16-19, and then16 mg from Weeks 20-48.
• Placebo Comparator: Placebo
  Participants received Mazdutide matched placebo subcutaneously once weekly from Weeks 0 to 48.

Primary Outcome Measure

Percent Change From Baseline in Body Weight at Week 32 [ Time Frame: Baseline, Week 32 ]

Locations (29)

Related coverage on Hipa.ai

• Mazdutide Phase 2 Trial for Obesity Shows Up to -22.3% Weight Reduction
  Mazdutide · Apr 21, 2026 · ClinicalTrials.gov

Find similar trials in Chandler, AZ

Related Studies

• Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
  PHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
• Study to Investigate Genetic Causes of Severe Early Childhood Onset Obesity.
  Recruiting · Columbia University · Boston, Massachusetts
• Investigating the Impact of Obesity on Pubertal Development in Girls
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina
• Metabolic Effects of Angiotensin-(1-7)
  PHASE1 · Recruiting · Vanderbilt University · Nashville, Tennessee